Long-Term Survival of Grafted Cells, Dopamine Synthesis/Release, Receptor Activity, and Functional Recovery after Grafting of Fetal Nigral Cells in Model Animals of Hemi-Parkinson’s Disease

Author(s):  
Hitoo Nishino ◽  
Takeshi Hashitani ◽  
Kiminao Mizukawa ◽  
Norio Ogawa ◽  
Sadao Shiosaka
1997 ◽  
Vol 148 (1) ◽  
pp. 135-146 ◽  
Author(s):  
Clive N. Svendsen ◽  
Maeve A. Caldwell ◽  
Jinkun Shen ◽  
Melanie G. ter Borg ◽  
Anne E. Rosser ◽  
...  

2002 ◽  
Vol 103 (s47) ◽  
pp. 67P-67P
Author(s):  
T. Harrower ◽  
E. Ratcliffe ◽  
A Richards ◽  
S. Dunnett ◽  
R. Bark

1997 ◽  
Vol 42 (1) ◽  
pp. 95-107 ◽  
Author(s):  
Gregor K. Wenning ◽  
Per Odin ◽  
Paul Morrish ◽  
Stig Rehncrona ◽  
Håkan Widner ◽  
...  

2005 ◽  
Vol 253 (1) ◽  
pp. 33-37 ◽  
Author(s):  
M. D'Amelio ◽  
P. Ragonese ◽  
L. Morgante ◽  
A. Reggio ◽  
G. Callari ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Emilie Hollville ◽  
Valerie Joers ◽  
Ayumi Nakamura ◽  
Vijay Swahari ◽  
Malú G. Tansey ◽  
...  

Abstract Mitochondrial quality control is essential for the long-term survival of postmitotic neurons. The E3 ubiquitin ligase Parkin promotes the degradation of damaged mitochondria via mitophagy and mutations in Parkin are a major cause of early-onset Parkinson’s disease (PD). Surprisingly however, mice deleted for Parkin alone are rather asymptomatic for PD-related pathology, suggesting that other complementary or redundant mitochondrial quality control pathways may exist in neurons. Mitochondrial damage is often accompanied by the release of toxic proteins such as cytochrome c. We have reported that once in the cytosol, cytochrome c is targeted for degradation by the E3 ligase CUL9 in neurons. Here we examined whether CUL9 and Parkin cooperate to promote optimal neuronal survival in vivo. We generated mice deficient for both Cul9 and Parkin and examined them for PD-related phenotypes. Specifically, we conducted assays to examine behavioural deficits (locomotor, sensory, memory and learning) and loss of dopaminergic neurons in both males and females. Our results show that the loss of Cul9 and Parkin together did not enhance the effect of Parkin deficiency alone. These results indicate that while both Parkin and CUL9 participate in mitochondrial quality control, neurons likely have multiple redundant mechanisms to ensure their long-term survival.


1994 ◽  
Vol 35 (2) ◽  
pp. 172-180 ◽  
Author(s):  
Olle Lindvall ◽  
Guy Sawle ◽  
Håkan Widner ◽  
John C. Rothwell ◽  
Anders Björklund ◽  
...  

2020 ◽  
Vol 18 (10) ◽  
pp. 758-768 ◽  
Author(s):  
Khadga Raj ◽  
Pooja Chawla ◽  
Shamsher Singh

: Tramadol is a synthetic analog of codeine used to treat pain of moderate to severe intensity and is reported to have neurotoxic potential. At therapeutic dose, tramadol does not cause major side effects in comparison to other opioid analgesics, and is useful for the management of neurological problems like anxiety and depression. Long term utilization of tramadol is associated with various neurological disorders like seizures, serotonin syndrome, Alzheimer’s disease and Parkinson’s disease. Tramadol produces seizures through inhibition of nitric oxide, serotonin reuptake and inhibitory effects on GABA receptors. Extensive tramadol intake alters redox balance through elevating lipid peroxidation and free radical leading to neurotoxicity and produces neurobehavioral deficits. During Alzheimer’s disease progression, low level of intracellular signalling molecules like cGMP, cAMP, PKC and PKA affect both learning and memory. Pharmacologically tramadol produces actions similar to Selective Serotonin Reuptake Inhibitors (SSRIs), increasing the concentration of serotonin, which causes serotonin syndrome. In addition, tramadol also inhibits GABAA receptors in the CNS has been evidenced to interfere with dopamine synthesis and release, responsible for motor symptoms. The reduced level of dopamine may produce bradykinesia and tremors which are chief motor abnormalities in Parkinson’s Disease (PD).


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Torsten Falk ◽  
Nicole R. Congrove ◽  
Shiling Zhang ◽  
Alexander D. McCourt ◽  
Scott J. Sherman ◽  
...  

Human retinal pigment epithelial (hRPE) cells have been tested as a cell-based therapy for Parkinson’s disease but will require additional study before further clinical trials can be planned. We now show that the long-term survival and neurotrophic potential of hRPE cells can be enhanced by the use of FDA-approved plastic-based microcarriers compared to a gelatin-based microcarrier as used in failed clinical trials. The hRPE cells grown on these plastic-based microcarriers display several important characteristics of hRPE foundin vivo: (1) characteristic morphological features, (2) accumulation of melanin pigment, and (3) high levels of production of the neurotrophic factors pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor-A (VEGF-A). Growth of hRPE cells on plastic-based microcarriers led to sustained levels (>1 ng/ml) of PEDF and VEGF-A in conditioned media for two months. We also show that the expression of VEGF-A and PEDF is reciprocally regulated by activation of the GPR143 pathway. GPR143 is activated by L-DOPA (1 μM) which decreased VEGF-A secretion as opposed to the previously reported increase in PEDF secretion. The hRPE microcarriers are therefore novel candidate delivery systems for achieving long-term delivery of the neuroprotective factors PEDF and VEGF-A, which could have a value in neurodegenerative conditions such as Parkinson’s disease.


Sign in / Sign up

Export Citation Format

Share Document